Journal of Medicinal Chemistry p. 9768 - 9772 (2015)
Update date:2022-08-04
Topics:
Genin, Michael J.
Bueno, Ana B.
Agejas Francisco, Javier
Manninen, Peter R.
Bocchinfuso, Wayne P.
Montrose-Rafizadeh, Chahrzad
Cannady, Ellen A.
Jones, Timothy M.
Stille, John R.
Raddad, Eyas
Reidy, Charles
Cox, Amy
Michael, M. Dodson
Michael, Laura F.
The farnesoid X receptor (FXR) is a member of the "metabolic" subfamily of nuclear receptors. Several FXR agonists have been reported in the literature to have profound effects on plasma lipids in animal models. To discover novel and effective therapies for dyslipidemia and atherosclerosis, we have developed a series of potent FXR agonists that robustly lower plasma LDL and vLDL in LDLr-/- mice. To this end the novel piperidinylisoxazole system LY2562175 was discovered. This molecule is a potent and selective FXR agonist in vitro and has robust lipid modulating properties, lowering LDL and triglycerides while raising HDL in preclinical species. The preclinical ADME properties of LY2562175 were consistent with enabling once daily dosing in humans, and it was ultimately advanced to the clinic for evaluation in humans. The synthesis and biological profile of this molecule is discussed.
View MoreShangyu Sanhechemicals Co.,LTD.
Contact:86-0571-56696839
Address:Num.2952,Nanhuan Road,Binjiang District,Hangzhou,China
Contact:
Address:No.89,Xinhua Road, Langfang City,Hebei China
website:http://www.fwdchem.com
Contact:86-21-54450828
Address:Room 802,Lotus Tower ,159 Tianzhou Road,Xuhui District,Shanghai
Liaoning Yufeng Chemical Co.,Ltd.
Contact:86-0419-3418888
Address:The metallurgical industrial zone,shoushan town, Liaoyang, Liaoning, China
Shandong Shouguang Songchuan Industrial Additives Co.,Ltd
Contact:+86-536-8566856
Address:Shouguang,Shandong,China
Doi:10.3987/COM-08-S(N)118
(2008)Doi:10.1039/b816104f
(2008)Doi:10.1016/0008-6215(86)85071-6
(1986)Doi:10.1039/b810600b
(2008)Doi:10.1002/ardp.200800034
(2008)Doi:10.1016/j.jorganchem.2008.09.063
(2009)